New Pill Reduces ‘Bad’ Cholesterol Levels by Almost 60%

Translate to Spanish or other 102 languages!

The study recruited people with heterozygous familial hypercholesterolemia, a genetic condition that causes the individual to have high levels of LDL, or “bad” cholesterol. Image for illustration purposes
The study recruited people with heterozygous familial hypercholesterolemia, a genetic condition that causes the individual to have high levels of LDL, or “bad” cholesterol. Image for illustration purposes
- Advertisement -

Medical News Today

A recent study published in JAMA on November 9, investigates a drug called enlicitide. 

The study recruited people with heterozygous familial hypercholesterolemia, a genetic condition that causes the individual to have high levels of LDL, or “bad” cholesterol.

- Advertisement -

For these individuals, lifestyle changes and statins are often inadequate to bring their levels of LDL cholesterol down.

Follow the link below to Medical News Today to read the full story:

https://www.medicalnewstoday.com/articles/oral-pill-enlicitide-reduces-bad-cholesterol-levels-statins?utm_term=feature&utm_source=Sailthru%20Email&utm_medium=Email&utm_campaign=MNT%20Daily%20News&utm_content=2025-11-26&apid=&rvid=4ba4ec80177cae00eabc43b8bc6648d598c4a356d104663735777e0a0f8b5c9f

Information source: https://www.medicalnewstoday.com

- Advertisement -

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

DHR Health Recognizes November as “National Hospice and Palliative Care” Month

DHR Health is pleased to recognize November as “National Hospice and Palliative Care Month.”  As we highlight National Hospice and Palliative Care Month, let us remember that healthcare is not solely about treating diseases but also about care for people at end of life.

STHS Heart Earns Healthgrades Five-Star Rating for Pacemaker Procedures

Healthgrades, the leading online resource for information about physicians and hospitals, has named STHS Heart a Five-Star Recipient for Pacemaker Procedures in 2027 for the second consecutive year, recognizing the facility's superior clinical outcomes and commitment to patient care.

AMA Advises Patients to Check with Doctors on Web Advice

The internet offers no shortage of health advice. But with misleading medical claims spread across social media, search engines, and AI platforms, finding trustworthy answers can be a challenge. 

FDA Authorizes Focused Ultrasound Treatment for Varicose Veins

Theraclion has announced that the US Food and Drug Administration (FDA) has granted De Novo authorization for its Sonovein device to treat superficial venous reflux in great saphenous veins (GSV), the main cause of varicose veins. This is the first noninvasive focused ultrasound platform to treat varicose veins, which affect approximately one third of adults.
- Advertisement -